LIFR — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4598944	0.82	4/20
SCHEMBL4426866	0.80	4/20
SCHEMBL4838231	0.79	4/20
SCHEMBL4426173	0.78	4/20
SCHEMBL4427080	0.75	4/20
SCHEMBL4429498	0.75	4/20
SCHEMBL1179413	0.73	4/20
SCHEMBL2152059	0.72	4/20
SCHEMBL1179318	0.72	4/20
SCHEMBL1179677	0.72	4/20
SCHEMBL4425090	0.72	4/20
SCHEMBL4425112	0.72	4/20
SCHEMBL4553647	0.71	4/20
SCHEMBL4426868	0.71	4/20
SCHEMBL4424559	0.70	4/20
SCHEMBL4425427	0.70	4/20
SCHEMBL4840215	0.70	4/20
SCHEMBL4421519	0.70	4/20
SCHEMBL4838926	0.70	4/20
SCHEMBL4837132	0.69	4/20

Clinical trials — most relevant to LIFR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Outcomes of ICSI Cycles With and Without Letrozole	PHASE4	UNKNOWN
Endometrial Preparation in Frozen Embryo Transfer Cycles	PHASE4	UNKNOWN
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF	PHASE3	COMPLETED
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents	PHASE3	ACTIVE_NOT_RECRUITING
Erythropoietin Therapy for Subarachnoid Hemorrhage	PHASE2	COMPLETED
Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer	PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma	PHASE2	COMPLETED
Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors	PHASE1	COMPLETED
Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia	PHASE1	SUSPENDED
Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD	PHASE1	COMPLETED
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers	PHASE1	COMPLETED
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia	PHASE1	RECRUITING
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML	PHASE1	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Prospective Monocentric Clinical-biological Database	nan	RECRUITING
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer	nan	UNKNOWN
Immune Checkpoint Receptors in AML-Leukemic Initiating Cells	nan	COMPLETED
TIGIT in Patients With Chronic Myeloid Leukemia	nan	UNKNOWN
Emerging Role of NOTCH-related Long Non-coding RNA(s) as Biomarkers in Liquid Biopsy From Colorectal Cancer Patients	nan	COMPLETED
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	nan	UNKNOWN
The Role of Erythropoietin in Myelodysplastic Syndrome	nan	COMPLETED
Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML	nan	RECRUITING
CircularRNA-microRNA-mRNA Regulatory Axis in IVF	nan	NOT_YET_RECRUITING
Biomarkers in Young Patients With Acute Myeloid Leukemia	nan	COMPLETED
Short-Term Application of Tocilizumab Following Myocardial Infarction	nan	COMPLETED
Intrauterine Infusion of GCSF and Reproductive Outcomes in Infertile Women with History of RIF	nan	COMPLETED
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome	nan	COMPLETED
Role of LILRA3 in Ankylosing Spondylitis and Axial Psoriatic Patients	nan	UNKNOWN
Assessment of Natural Killer Cells in Unexplained Recurrent Pregnancy Loss	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a LIFR binder may also engage these)

Protein	Name	Similarity
Q5XNR9	—	1.000	Q5XNR9 →
P42703	—	0.999	P42703 →
O70535	—	0.998	O70535 →
Q99650	—	0.994	Q99650 →
Q65Z14	—	0.993	Q65Z14 →
Q8K5B1	—	0.990	Q8K5B1 →
Q95LF0	—	0.990	Q95LF0 →
O70458	—	0.990	O70458 →
Q764M8	—	0.989	Q764M8 →
O09030	—	0.989	O09030 →
Q14627	—	0.988	Q14627 →
IFNAR1	Interferon alpha/beta receptor 1	0.987	landscape →
Q8NI17	—	0.987	Q8NI17 →
Q8K4B4	—	0.987	Q8K4B4 →
P48095	—	0.987	P48095 →
Q9MYL0	—	0.986	Q9MYL0 →
P29460	—	0.985	P29460 →
P43432	—	0.985	P43432 →
P48356	—	0.985	P48356 →
O88786	—	0.985	O88786 →
IL23R	Interleukin-23 receptor	0.985	landscape →
Q62959	—	0.984	Q62959 →
Q99665	—	0.984	Q99665 →
Q9BEG2	—	0.984	Q9BEG2 →
P33896	—	0.984	P33896 →
Q62611	—	0.983	Q62611 →
P78552	—	0.983	P78552 →
Q8MJS1	—	0.983	Q8MJS1 →
P46658	—	0.983	P46658 →
O02744	—	0.983	O02744 →